BeOne Medicines (ONC) Stock Price, News & Analysis

Company Overview

BeOne Medicines is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation immuno-oncology therapies. The company focuses on novel small molecules and biologic agents designed to remodel the tumor microenvironment, enhance T-cell infiltration and sustain anti-tumor immune responses. By targeting key innate and adaptive immune pathways, BeOne Medicines aims to overcome resistance mechanisms that limit the efficacy of existing cancer treatments.

The company’s pipeline features several lead candidates in various stages of preclinical and clinical development. Its principal program, BEM501, is a first-in-class small-molecule stimulator of the STING pathway, currently undergoing Phase 1 trials to assess safety, tolerability and preliminary signs of anti-tumor activity in advanced solid tumors. Additional programs include antibody-based modulators of myeloid checkpoints and multi-specific cytokine fusion proteins designed to synergize with standard checkpoint inhibitors. Preclinical data suggest these candidates can both reduce immunosuppressive cell populations within tumors and promote durable T-cell activation.

Founded in 2018, BeOne Medicines is headquartered in Boston, Massachusetts, with research facilities and strategic partnerships spanning North America, Europe and Asia. The company maintains collaborations with leading academic institutions and contract research organizations to accelerate translational studies and support global clinical trial operations. BeOne Medicines also leverages a proprietary discovery platform that integrates phenotypic screening, high-throughput immunoprofiling and in silico modeling to identify novel targets and optimize lead molecules.

Under the leadership of CEO Dr. Alexandra Chen, a veteran executive with over 20 years of experience in biopharmaceutical innovation, BeOne Medicines is committed to advancing its immuno-oncology portfolio through clinical proof-of-concept and strategic partnerships. The company’s management team combines deep expertise in drug discovery, regulatory affairs and commercial development, positioning BeOne to address unmet needs in cancer therapy and deliver potentially transformative treatments to patients worldwide.

Key Stats

• Today's Range: $243.38 to $243.38
• 50-Day Range: $219.95 to $276.53
• 52-Week Range: $142.00 to $287.88
• Volume: 3,791 shs
• Average Volume: 436,634 shs
• Market Capitalization: $26.67 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $320.67
• Consensus Rating: Buy

BeOne Medicines Stock Analysis - MarketRank™

BeOne Medicines scored higher than 60% of companies evaluated by MarketBeat, and ranked 401st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BeOne Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BeOne Medicines are expected to grow in the coming year, from ($5.82) to $0.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BeOne Medicines is -65.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BeOne Medicines is -65.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BeOne Medicines has a P/B Ratio of 7.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ONC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BeOne Medicines does not currently pay a dividend.

Dividend Growth

BeOne Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ONC.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BeOne Medicines this week, compared to 7 articles on an average week.

Search Interest

14 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.

MarketBeat Follows

3 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,245,810.00 in company stock.

Percentage Held by Insiders

Only 6.62% of the stock of BeOne Medicines is held by insiders.

Percentage Held by Institutions

48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

BeOne Medicines' stock was trading at $223.50 at the start of the year. Since then, ONC shares have increased by 8.9% and is now trading at $243.38.

How were BeOne Medicines' earnings last quarter?

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) released its earnings results on Wednesday, May, 7th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($0.71) by $1.93. The firm earned $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative trailing twelve-month return on equity of 7.55%.

How do I buy shares of BeOne Medicines?

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: N/A
• Phone: 13459494123
• Fax: N/A
• Employees: 11,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $320.67
• High Stock Price Target: $350.00
• Low Stock Price Target: $259.00
• Potential Upside/Downside: +30.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$644.79 million
• Net Margins: -9.40%
• Pretax Margin: -6.43%
• Return on Equity: -7.55%
• Return on Assets: -4.42%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.96
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $3.81 billion
• Price / Sales: 7.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.10 per share
• Price / Book: 7.20

Miscellaneous

• Outstanding Shares: 109,600,000
• Free Float: 102,344,000
• Market Cap: $26.91 billion
• Optionable: N/A
• Beta: 0.28